Our Take
Europe has the clinical evidence and ROI data to cover GLP-1 drugs at scale, but treats obesity as a lifestyle choice rather than chronic disease—a policy failure masquerading as caution.
Why it matters
Pharmaceutical companies and health systems are locked in a stalemate: drugs work, employers save money on sick days, yet only 2-3% of eligible European patients access treatment versus 10% in the US. The gap is not medical; it is regulatory and cultural.
Do this week
Health economics teams: collate real-world evidence on sickness-day reduction and employer ROI by end of Q3 to force coverage conversations with local payers before 2027 budget cycles lock.
Only 2-3% of eligible Europeans use obesity drugs, while US adoption hits 10%
At HLTH Europe 2026 in Amsterdam, industry panellists confirmed that glucagon-like peptide 1 receptor agonists (GLP-1RAs) like Novo Nordisk's semaglutide are delivering measurable clinical wins across the continent. Weight loss approaches bariatric surgery outcomes. Patient engagement is surging: top Ozempic videos on TikTok logged 70 million views (per Voy CMO Earim Chaudry). The obesity drug market is forecast to hit $173.5 billion across major markets by 2031 (per GlobalData estimate).
Yet adoption in Europe lags drastically. Vince Lamanna, SVP Region Europe and Canada at Novo Nordisk, noted that only 2-3% of eligible European patients receive GLP-1RAs compared to 10% in the US. The barrier is not efficacy. It is coverage.
Most European public health systems do not currently reimburse obesity medications. Germany, for example, classifies obesity by law as a lifestyle choice rather than disease. Italy only recently passed legislation recognizing obesity as chronic. This legal framing cascades: if obesity is not a disease, insurers argue, why pay for treatment?
Real-world data proves GLP-1s save money, but policy still treats them as discretionary
The case for coverage is no longer theoretical. Oviva co-founder Kai Eberhardt reported that patients on the company's care pathway showed a 50% reduction in sickness days within six months (company-reported). Weight Watchers CCO Scott Honken added that combining medication with behavioural support yields an additional 29% weight loss versus medication alone at 12 months (company-reported).
These gains translate to employer savings and productivity recovery, a direct ROI story that should unlock public coverage. Yet European health systems have not moved. Chaudry flagged the real cost: slower rollout means healthcare services do not see the return on investment that would justify wider adoption.
Beneath the coverage gap lies deeper structural rot. Obesity is not a core part of medical education despite 15 years of evidence that it is a metabolic disease, not a moral failing. Patient stigma runs high: 55% of patients on weight loss medications hide the fact from partners, leading to treatment discontinuation. Doctors carry the same bias. Until medical training and cultural attitudes shift, payers will move slowly and call it prudent.
Collect long-term discontinuation data now
Manufacturers and integrated care providers must move beyond 12-month benchmarks. The real liability is weight rebound after treatment stops. Honken flagged this explicitly: the industry needs real-world evidence on how weight loss is maintained over time. Without it, payers have a legitimate excuse to deny coverage, citing unknown durability.
Chaudry was blunt: "Medications are the start, not the destination." Models of care, sustainability, and systemic change must precede widespread deployment. The countries that move first on comprehensive obesity as chronic disease (as Italy has done legislatively) will define the standard. Others will follow, slowly.